Dian Diagnostics Group Co.,Ltd. (300244.SZ) Bundle
Dian Diagnostics Group's latest numbers tell a nuanced story that investors should scrutinize: operating revenue fell to CNY 12.196 billion in 2024 (a 9.04% decline) and dropped further in Q1 2025 to CNY 2.938 billion (a 20.45% year‑on‑year fall), even as Q1 gross margin improved to 26.39%; the company reported a net loss of CNY 357 million in 2024 (a 216.20% decline), while specialty testing showed pockets of strength-CNY 1.822 billion in revenue with pathogen infection up 57%, hematological oncology up 51% and neuroimmunology up 38%-and liquidity metrics include CNY 1.82 billion cash on hand, total debt of CNY 2.47 billion (debt/equity 28.70%) and a current ratio of 2.65, set against valuation cues like a trailing P/E of 39.22 and forward P/E of 18.02 and a forward dividend yield of 6.85%; read on for a line‑by‑line breakdown of profitability, leverage, valuation and the operational risks and growth drivers shaping Dian's outlook.
Dian Diagnostics Group Co.,Ltd. (300244.SZ) - Revenue Analysis
Dian Diagnostics Group reported operating revenue of CNY 12.196 billion for 2024, representing a 9.04% decline versus 2023. The company entered 2025 with continued top-line pressure: Q1 2025 revenue fell 20.45% year‑on‑year to CNY 2.938 billion. Gross margin improved slightly to 26.39% in Q1 2025, up 0.86 percentage points year‑on‑year, while improvements in working capital management contributed to stronger operating cash flow late in 2024.- 2024 operating revenue: CNY 12.196 billion (-9.04% YoY)
- Q1 2025 revenue: CNY 2.938 billion (-20.45% YoY)
- Q1 2025 gross margin: 26.39% (+0.86 pp YoY)
- Q4 2024 net cash from operations: CNY 1.153 billion (up from CNY 333 million in Q3 2024)
- Pathogen infection testing: +57% year‑on‑year
- Hematological oncology testing: +51% year‑on‑year
- Neuroimmunology testing: +38% year‑on‑year
| Metric | Amount (CNY) | Change |
|---|---|---|
| Operating revenue (2024) | 12,196,000,000 | -9.04% YoY |
| Revenue (Q1 2025) | 2,938,000,000 | -20.45% YoY |
| Diagnostic services revenue | 4,520,000,000 | -12.86% YoY |
| ICL business contribution | 4,173,000,000 | - |
| Specialty testing revenue | 1,822,000,000 | 40.31% of diagnostic services |
| Pathogen infection growth | - | +57% YoY |
| Hematological oncology growth | - | +51% YoY |
| Neuroimmunology growth | - | +38% YoY |
| Gross margin (Q1 2025) | 26.39% | +0.86 pp YoY |
| Net cash from operations (Q4 2024) | 1,153,000,000 | Up from 333,000,000 in Q3 2024 |
Dian Diagnostics Group Co.,Ltd. (300244.SZ) - Profitability Metrics
Key profitability outcomes for Dian Diagnostics Group Co.,Ltd. in 2024 reflect material deterioration in bottom-line performance alongside modest operating profitability sustaining positive operating margin.
- Net loss in 2024: CNY 357 million (a 216.20% decrease vs. prior year).
- Net profit margin (2024): -1.39%, a decline of 5.73 percentage points year‑on‑year.
- Operating margin (2024): 3.06%, down from 3.67% in 2023.
- Return on assets (ROA, 2024): 1.72%, down from 1.29% in 2023.
- Return on equity (ROE, 2024): -2.59%, a decline from -2.82% in 2023.
- Profit margin (2024): -3.46%, versus -3.84% in 2023.
| Metric | 2023 | 2024 | YoY Change |
|---|---|---|---|
| Net Profit / (Loss) | - (implied smaller loss or profit) | -(CNY)357,000,000 | -216.20% |
| Net Profit Margin | 4.34% (implied from change) | -1.39% | -5.73 pp |
| Operating Margin | 3.67% | 3.06% | -0.61 pp |
| Return on Assets (ROA) | 1.29% | 1.72% | - (reported as decline) |
| Return on Equity (ROE) | -2.82% | -2.59% | Reported decline vs. prior year |
| Profit Margin | -3.84% | -3.46% | Improvement of 0.38 pp (reported as decrease) |
- Operating margin remaining positive at 3.06% indicates core business still generates gross operating profits before non-operating items drove the net loss.
- The large net loss and negative net profit margin highlight one-off charges, financing costs or impairment impacts that investors should investigate in financial notes.
- ROA and ROE movements suggest asset efficiency and equity returns remain under pressure despite mixed directional reporting; reconcile with balance sheet changes and capital structure shifts.
For full investor context and holder dynamics see: Exploring Dian Diagnostics Group Co.,Ltd. Investor Profile: Who's Buying and Why?
Dian Diagnostics Group Co.,Ltd. (300244.SZ) - Debt vs. Equity Structure
- Total debt (as of June 30, 2025): CNY 2.47 billion.
- Total cash on hand: CNY 1.82 billion (cash per share: CNY 2.96).
- Net debt: CNY 0.65 billion (CNY 2.47B - CNY 1.82B).
- Debt-to-equity ratio: 28.70% - indicating modest leverage relative to shareholders' equity.
- Book value per share: CNY 10.48.
- Current ratio: 2.65 - suggests solid short-term liquidity.
- Forward annual dividend: CNY 1.00 per share; yield: 6.85%; payout ratio: 73.21%.
| Metric | Value |
|---|---|
| Total Debt | CNY 2.47 billion |
| Total Cash | CNY 1.82 billion |
| Net Debt | CNY 0.65 billion |
| Debt-to-Equity Ratio | 28.70% |
| Book Value per Share | CNY 10.48 |
| Cash per Share | CNY 2.96 |
| Current Ratio | 2.65 |
| Forward Annual Dividend | CNY 1.00 / share |
| Dividend Yield | 6.85% |
| Payout Ratio | 73.21% |
- Leverage profile: with net debt of CNY 0.65B and D/E of 28.70%, the balance sheet shows conservative leverage versus typical industry ranges.
- Liquidity stance: current ratio 2.65 and CNY 1.82B cash provide a buffer for short-term obligations and operational needs.
- Capital return policy: a 6.85% yield and a high payout ratio (73.21%) indicate a shareholder-friendly distribution, though the payout level could limit reinvestment capacity.
- Book value and cash per share give investors direct per-share measures to assess balance-sheet backing (book value CNY 10.48; cash per share CNY 2.96).
Dian Diagnostics Group Co.,Ltd. (300244.SZ) - Liquidity and Solvency
Dian Diagnostics Group displays a liquidity profile that supports near-term obligations while maintaining moderate leverage. Key headline metrics and recent cash-flow trends provide a clearer picture of the company's capacity to operate and return capital to shareholders.- Current ratio: 2.65 - indicates the company has CNY 2.65 in short-term assets for every CNY 1.00 of short-term liabilities, a comfortable short-term coverage buffer.
- Quick ratio: not specified - would strip out inventory to show immediate liquidity.
- Cash ratio: not specified - would measure pure cash and equivalents against short-term liabilities.
| Metric | Value | Notes |
|---|---|---|
| Current ratio | 2.65 | Healthy short-term coverage |
| Operating cash flow (Q3 2024) | CNY 333 million | Prior quarter |
| Operating cash flow (Q4 2024) | CNY 1,153 million | Significant quarter-on-quarter improvement |
| Total debt-to-equity ratio | 28.70% | Moderate financial leverage |
| Forward annual dividend yield | 6.85% | Attractive yield for income investors |
| Payout ratio | 73.21% | High share of earnings returned as dividends |
- Cash-flow dynamics: Operating cash flow jumped from CNY 333M in Q3 2024 to CNY 1,153M in Q4 2024, improving liquidity and potentially funding operations, capex, and dividends without incremental borrowing.
- Dividend sustainability: A forward yield of 6.85% with a 73.21% payout ratio signals a generous distribution; the elevated payout ratio warrants monitoring of earnings and cash-flow consistency to confirm sustainability.
- Leverage context: A debt-to-equity of 28.70% suggests the company is not highly leveraged, leaving room to absorb shocks or pursue modest debt-funded investments if needed.
- Missing granular liquidity metrics: Without the quick and cash ratios, investors should review the composition of current assets (cash, receivables, inventory) to judge how much of the 2.65 current ratio translates into immediately available liquidity.
Dian Diagnostics Group Co.,Ltd. (300244.SZ) Valuation Analysis
As of July 5, 2025, key market multiples and price metrics for Dian Diagnostics Group Co.,Ltd. (300244.SZ) show a stock trading at a premium on earnings relative to forward expectations while exhibiting moderate revenue and book-value coverage. The following table and bullet points synthesize the headline valuation figures and near-term market context investors commonly use when assessing entry points and relative risk.
| Metric | Value | Notes |
|---|---|---|
| Trailing P/E | 39.22 | Reflects past 12 months' earnings multiple |
| Forward P/E | 18.02 | Market-implied earnings multiple for next 12 months |
| Price-to-Sales (TTM) | 0.79 | Indicates price relative to trailing revenue |
| Price-to-Book (MRQ) | 1.36 | Market price relative to most-recent quarter book value |
| Enterprise Value / Revenue | 1.12 | EV scaled to top-line; useful for capital structure-neutral comparison |
| Enterprise Value / EBITDA | 15.88 | EV relative to operating cash-profit |
| 52-Week Range | CNY 8.90 - CNY 21.75 | Volatility range over prior 12 months |
| 50-Day Moving Average | CNY 16.08 | Short-to-medium term trend |
| 200-Day Moving Average | CNY 14.63 | Long-term trend |
| Beta | 0.47 | Lower volatility vs. market |
- High trailing P/E (39.22) vs. materially lower forward P/E (18.02) suggests analysts expect earnings growth or that recent trailing earnings were depressed.
- Price-to-sales of 0.79 implies the market values less than one yuan per yuan of trailing sales, a moderate revenue valuation relative to some healthcare peers.
- Price-to-book at 1.36 signals modest premium to book value - neither deeply cyclical nor richly capitalized on balance sheet fair value.
- EV/Revenue of 1.12 and EV/EBITDA of 15.88 position the company as having reasonable revenue valuation but a higher multiple on operating profitability, highlighting margin expectations.
- Beta 0.47 points to defensiveness; the stock may underreact to market swings but also lag in risk-on rallies.
Technical and momentum context:
- Current price sits between the 50-day (CNY 16.08) and 200-day (CNY 14.63) moving averages, indicating medium-term strength over long-term trend.
- Trading range (CNY 8.90-21.75) provides visible support/resistance zones for tactical entries and stops.
For deeper investor positioning and shareholder composition details, see: Exploring Dian Diagnostics Group Co.,Ltd. Investor Profile: Who's Buying and Why?
Dian Diagnostics Group Co.,Ltd. (300244.SZ) - Risk Factors
Dian Diagnostics Group faces a challenging operating environment marked by regulatory pressure, market competition, and deteriorating profitability metrics in 2024. The following risk factors are material for investors assessing the company's financial health and near-term outlook.
- Regulatory and policy risk: intensified medical anti-corruption enforcement can reduce procurement volumes, delay contracts, and compress margins for diagnostic suppliers.
- Competitive pressure: increased rivalry from domestic and international diagnostics firms risks market share erosion and pricing pressure, further undermining revenue growth.
- Profitability deterioration: key margin and return metrics weakened in 2024, increasing the likelihood of extended losses if revenue recovery lags.
- Cash-flow and solvency concerns: a substantial net loss raises liquidity risk and could constrain capital expenditure, R&D, and working capital financing.
- Operational risk: dependence on hospital and public-sector channels exposes the company to procurement cycle shifts and policy-driven demand changes.
- Execution risk: integration, product commercialization, and scale-up failures would exacerbate the current earnings pressure.
Key 2024 vs 2023 financial indicators:
| Metric | 2023 | 2024 | Change |
|---|---|---|---|
| Net profit margin | 4.34% (approx.) | -1.39% | -5.73 percentage points YoY |
| Net profit / (loss) | Profit (approx. CNY 120.6m) | Net loss CNY 357 million | Decrease 216.20% YoY |
| Operating margin | 3.67% | 3.06% | -0.61 percentage points |
| Return on equity (ROE) | -2.82% | -2.59% | 0.23 percentage points (less negative) |
| Profit margin (reported) | -3.84% | -3.46% | 0.38 percentage points (less negative) |
- Investor implications: heightened volatility in earnings; potential need for capital raises or cost restructuring if losses persist.
- Monitoring checklist: policy developments on anti-corruption, tender/pricing trends, quarterly revenue recovery, cash-burn rate, and any management guidance changes.
Contextual and historical background on the company: Dian Diagnostics Group Co.,Ltd.: History, Ownership, Mission, How It Works & Makes Money
Dian Diagnostics Group Co.,Ltd. (300244.SZ) - Growth Opportunities
Dian Diagnostics is accelerating its digital transformation and product innovation, positioning itself to capture higher-margin testing revenue and improve operational cash flow.
- Digital transformation: launch of the 'Dian Medical Inspection Big Model' in collaboration with Huawei Cloud to enhance diagnostic AI, workflow automation, and remote diagnostic support.
- Specialty testing expansion: strategic focus on pathogen infection, hematological oncology, and neuroimmunology subsegments supported by clinical demand and higher per-test ASPs.
- ICL business recovery: management anticipates recovery in institutional channel labs (ICL) with improved utilization and collections, supporting 2025 revenue guidance.
- Shareholder returns: maintained cash dividends with a forward annual yield of 6.85% and a payout ratio of 73.21%.
| Metric | Value |
|---|---|
| 2025 Projected Revenue | CNY 12.381 billion |
| Revenue growth rate (2025) | 2% |
| Revenue growth rate (2026) | 6% |
| Revenue growth rate (2027) | 6% |
| Specialty testing revenue | CNY 1.822 billion |
| Specialty: pathogen infection growth | 57% |
| Specialty: hematological oncology growth | 51% |
| Specialty: neuroimmunology growth | 38% |
| Forward annual dividend yield | 6.85% |
| Payout ratio | 73.21% |
| 52-week stock price change | +42.26% |
| Beta (volatility) | 0.47 |
- Specialty testing drivers:
- Pathogen infection: 57% growth, driven by expanded molecular panels and infectious disease screening
- Hematological oncology: 51% growth, driven by NGS-based panels and MRD assays
- Neuroimmunology: 38% growth, driven by autoantibody panels and specialized CSF testing
- Operational levers:
- AI-assisted interpretation via the Dian Medical Inspection Big Model to raise throughput and reduce per-test labor time
- Improved cash flow management tied to ICL recovery and tighter receivables collection
- Dividend policy signaling commitment to returns (yield 6.85%, payout 73.21%) to attract income-focused investors
For a detailed view of the company's strategic direction and values, see Mission Statement, Vision, & Core Values (2026) of Dian Diagnostics Group Co.,Ltd.
Dian Diagnostics Group Co.,Ltd. (300244.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.